Are There Gender-Specific Differences Concerning Quality of Life in Treated Acromegalic Patients?

Abstract

Objective: Acromegaly is associated with deleterious comorbidities that can remain irreversible even after successful cure has been achieved and lead to a persistently impaired Quality of Life (QoL). The aim of the study was to assess frequency and degree of persistent comorbidities and complaints after treatment of acromegaly and to investigate their impact on QoL. Another scope of interest was to determine gender-specific factors that influence perceived QoL in men and women.

Methods: We developed an Acromegaly Comorbidities & Complaints Questionnaire (ACCQ) consisting of 8 items (e. g. acral enlargement, joint complaints, hypertension, diabetes) known to affect QoL in order to assess frequency and degree of comorbidities. Additionally, the Acromegaly Quality of Life Questionnaire (AcroQoL) and the Short-form 36 (SF-36) questionnaire were handed out to 55 treated acromegalic patients.

Results: Both genders suffer from a lasting impairment in quality of life to a considerable degree. Complaints impairing manual skills (e. g. acral enlargement, arthralgias) were the most frequent findings (73% of all participants) in both genders. Multivariate analyses revealed that in men numbness of fingers and persistent joint-complaints were decisively responsible for impaired QoL. In women, it was the persistence of hypertension.

Conclusions: Persistent joint complaints have adverse effects on QoL after treatment of acromegaly in men, possibly because they lead to impairment of manual motor skills and a handicap in their working life. Women seem to perceive late effects of hypertension as a manifest health threat.

Key words

comorbidities - complaints - quality of life - acromegaly - gender-differences

References

• 1 Biermasz NR, van Thiel SW, Pereira AM. et al . Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess.  J Clin Endocrinol Metab. 2004;  89 5369-5376
• 2 Biermasz NR, Pereira AM, Smit JWA. et al . Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life.  J Clin Endocrinol Metab. 2005;  95 2731-2739
• 3 Bourdelot A, Coste J, Hazebroucq V. et al . Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.  Eur J Endocrinol. 2004;  150 763-771
• 4 Colao A, Ferone D, Marzullo P. et al . Systemic complications of acromegaly: epidemiology, pathogenesis, and management.  Endocr Rev. 2004;  25 102-152
• 5 Daly AF, Petrossians P, Beckers A. An overview of the epidemiology and genetics of acromegaly.  J Endocrinol Invest. 2005;  28 67-69
• 6 Essau CA, Lewinsohn PM, Seeley JR. et al . Gender differences in the developmental course of depression.  J Affect Disord. 2010;  [Epub ahead of print]
• 7 Ezzat S, Snyder PJ, Young WF. et al . Octreotide treatment of acromegaly. A randomized, multicenter study.  Ann Intern Med. 1992;  117 711-718
• 8 Figueira ML, Ouakinin S. Gender-related endocrinological dysfunction and mental disorders.  Curr Opin Psychiatry. 2010;  23 369-372
• 9 Holdaway IM, Rajasoorya C. Epidemiology of acromegaly.  Pituitary. 1999;  2 29-41
• 10 Maison P, Tropeano AI, Macquin-Mavier I. et al . Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.  J Clin Endocrinol Metab. 2007;  92 1743-1747
• 11 Mallik S, Spertus JA, Reid KJ. et al . Depressive symptoms after acute myocardial infarction: evidence for highest rates in younger women.  Arch Intern Med. 2006;  166 876-883
• 12 Melmed S, Colao A, Barkan A. et al . Guidelines for acromegaly management: an update.  J Clin Endocrinol Metab. 2009;  94 1509-1517
• 13 Nabarro JD. Acromegaly.  Clin Endocrinol. 1987;  26 481-512
• 14 Norris CM, Hegadoren K, Pilote L. Depression symptoms have greater impact on the 1-year health related quality of life outcomes of women post-myocardial infarction compared to men.  Eur J Cardiovasc Nurs. 2007;  6 92-98
• 15 Psaras T, Milian M, Hattermann V. et al . Predictive factors for neurocognitive function and Quality of Life after surgical treatment for Cushing's disease and acromegaly [accepted for publication.  Journal of Endocrinological Investigation. 2010]; 
• 16 Psaras T, Milian M, Hattermann V. et al . Aftercare in patients with Cushing's disease and acromegaly: is there room for improvement?.  Acta Neurochir. 2010;  152 271-278
• 17 Rajasoorya C, Holdaway IM, Wrightson P. et al . Determinants of clinical outcome and survival in acromegaly.  Clin Endocrinol. 1994;  41 95-102
• 18 Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U. et al . Sex and gender differences in myocardial hypertrophy and heart failure.  Circ J. 2010;  74 1265-1273
• 19 Serri O, Robert F, Comtois R. et al . Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.  Clin Endocrinol. 1987;  27 429-436
• 20 Trepp R, Everts R, Stettler C. et al . Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL).  Clin Endocrinol. 2005;  63 103-110
• 21 van Haren-Willems J, Heijdra Y. Increasing evidence for gender differences in chronic obstructive pulmonary disease.  Womens Health (Lond Engl). 2010;  6 595-600
• 22 Ware Jr JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection.  Medical Care. 1992;  30 473-483
• 23 Webb SM, Prieto L, Badia X. et al . Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties.  Clin Endocrinol. 2002;  57 251-258
• 24 Zalihić A, Markotić V, Zalihić D. et al . Gender and quality of life after cerebral stroke.  Bosn J Basic Med Sci. 2010;  10 94-99

APPENDIX

Correspondence